/
MGX
$1.20-$0.05 (-4.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$47.1M
38M shares
52-week range
$1.13 – $3.95
2% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.63%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-9.11
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $243.0K | $17.2M | $44.8M | $52.3M | $25.2M |
| Cost of revenue | $387.0K | $1.7M | $94.4M | $0 | $5.3M |
| Gross profit | −$144.0K | $15.5M | −$49.6M | $52.3M | $19.9M |
| Gross margin | -59.3% | 89.9% | -110.9% | 100.0% | 78.9% |
| R&D | $14.5M | $43.1M | $94.4M | $109.2M | $94.4M |
| Operating income | −$23.9M | −$44.6M | −$78.5M | −$88.9M | −$96.0M |
| EBITDA | −$20.8M | −$39.2M | −$56.0M | −$78.2M | −$82.6M |
| Net income | −$21.4M | −$43.6M | −$68.3M | −$78.1M | −$87.9M |
| Net margin | -8823.9% | -253.4% | -152.5% | -149.3% | -348.5% |
| EPS (diluted) | -3.62 | -1.16 | -1.82 | -2.09 | -2.36 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12M | $-2.12 | $-2.33–$-1.91 | 2 |
| 2027 | $13M | $-1.57 | $-1.93–$-1.20 | 2 |
| 2028 | $20M | $-2.18 | $-3.32–$-0.98 | 1 |
| 2029 | $20M | $-1.95 | $-2.98–$-0.88 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Metagenomi Therapeutics, Inc. Common Stock
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
metagenomi.co- Employees
- 118
- IPO / List date
- Feb 9, 2024
- HQ
- EMERYVILLE, CA
Held by traders on TradeandTell
No one on the platform currently holds MGX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 787,900 | $1.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MGX yet.
